Liver Disease Therapeutics Market is estimated to increase at a growth rate of 10.2% CAGR over the forecast period from 2024 to 2030.
The global Liver Disease Therapeutics Marketstudy analyzes and forecasts the market size across 6 regions and 24 countries for diverse segments including By Treatment (Anti Viral Drugs, Targeted Therapy, Immunosuppressant Drugs, Chemotherapy Drugs, Immunoglobulin, Vaccines , Others), By End-User (Hospitals, Ambulatory Surgery Centers, Others).
An introduction to Liver Disease Therapeutics Market in 2024
The liver disease therapeutics market encompasses a wide range of pharmaceutical and biological treatments for liver diseases and disorders, including viral hepatitis, non-alcoholic fatty liver disease (NAFLD), alcoholic liver disease (ALD), autoimmune hepatitis, and liver cirrhosis. Liver disease therapeutics aim to alleviate symptoms, slow disease progression, and prevent complications associated with liver dysfunction, such as liver failure and hepatocellular carcinoma (HCC). Key categories of liver disease therapeutics include antiviral drugs, immunosuppressants, hepatoprotective agents, and bile acid modulators. Market growth is driven by factors such as the increasing prevalence of liver diseases, rising awareness of liver health, and advancements in drug discovery and development. Collaboration between pharmaceutical companies, academic researchers, and healthcare providers drives innovation in liver disease therapeutics, leading to the development of targeted therapies, combination regimens, and precision medicine approaches that improve treatment outcomes and enhance patient quality of life.
Liver Disease Therapeutics Market Trend: Focus on Non-Alcoholic Fatty Liver Disease (NAFLD) and Non-Alcoholic Steatohepatitis (NASH)
A significant trend in the Liver Disease Therapeutics market is the increasing focus on non-alcoholic fatty liver disease (NAFLD) and its progressive form, non-alcoholic steatohepatitis (NASH). With the rising prevalence of obesity, sedentary lifestyles, and metabolic syndrome worldwide, NAFLD/NASH has emerged as a leading cause of chronic liver disease and liver-related complications such as cirrhosis and hepatocellular carcinoma. This trend reflects the growing recognition of NAFLD/NASH as a significant public health concern and the need for effective therapeutic interventions to manage and prevent disease progression.
Liver Disease Therapeutics Market Driver: Growing Burden of Viral Hepatitis Infections
A key driver for the Liver Disease Therapeutics market is the growing burden of viral hepatitis infections, particularly hepatitis B virus (HBV) and hepatitis C virus (HCV). Viral hepatitis remains a major global health challenge, with millions of people affected by chronic hepatitis B or C infections, leading to liver inflammation, fibrosis, and cirrhosis. Despite advances in antiviral therapy, many patients with chronic hepatitis require long-term treatment to suppress viral replication and prevent disease progression. This driver fuels the demand for liver disease therapeutics, including antiviral drugs and immunomodulatory agents, to improve patient outcomes and reduce the burden of viral hepatitis-related liver disease.
Liver Disease Therapeutics Market Opportunity: Development of Novel Therapeutic Approaches Targeting Fibrosis and Liver Regeneration
An opportunity within the Liver Disease Therapeutics market lies in the development of novel therapeutic approaches targeting liver fibrosis and regeneration. Liver fibrosis, characterized by the excessive accumulation of scar tissue in response to chronic liver injury, is a common feature of various liver diseases, including NAFLD/NASH, viral hepatitis, and alcoholic liver disease. Therapies aimed at modulating fibrosis progression and promoting liver regeneration offer potential benefits in slowing disease progression, preventing liver failure, and improving overall liver function. By investing in research and development of innovative drugs targeting fibrosis pathways, stimulating liver regeneration, or promoting tissue repair, stakeholders in the liver disease therapeutics market can address unmet medical needs and contribute to the advancement of liver disease management and treatment.
Liver Disease Therapeutics Market Market Segmentation
By Treatment
Anti Viral Drugs
Targeted Therapy
Immunosuppressant Drugs
Chemotherapy Drugs
Immunoglobulin
Vaccines
Others
By End-User
Hospitals
Ambulatory Surgery Centers
Others
Geographical Analysis
North America (United States, Canada, Mexico)
Europe (Germany, France, United Kingdom, Spain, Italy, Rest of Europe)
Asia Pacific (China, India, Japan, South Korea, Rest of Asia Pacific)
South America (Brazil, Argentina, Rest of South America)
Middle East and Africa (Saudi Arabia, UAE, Rest of Middle East, South Africa, Egypt, Rest of Africa)
Liver Disease Therapeutics Market Companies
Abbott Laboratories
AbbVie Inc
Alnylam Pharmaceuticals Inc
Astellas Pharma Inc
Bristol-Myers Squibb Company
Endo International PLC
F. Hoffmann-La Roche Ltd.
Gilead Sciences
GlaxoSmithKline PLC
Merck & Co. Inc
Novartis AG
Pfizer Inc
Provectus Biopharmaceuticals Inc
Sanofi AG
Takeda Pharmaceutical
Reasons to Buy the Liver Disease Therapeutics Market Study
• Deepen your industry insights and navigate uncertainties for strategy formulation, CAPEX, and Operational decisions
• Gain access to detailed insights on the Liver Disease Therapeutics Market, encompassing current market size, growth trends, and forecasts till 2030.
• Access detailed competitor analysis, enabling competitive advantage through a thorough understanding of market players, strategies, and potential differentiation opportunities
• Stay ahead of the curve with insights on technological advancements, innovations, and upcoming trends
• Identify lucrative investment avenues and expansion opportunities within the Liver Disease Therapeutics Market industry, guided by robust, data-backed analysis.
• Understand regional and global markets through country-wise analysis, regional market potential, regulatory nuances, and dynamics
• Execute strategies with confidence and speed through information, analytics, and insights on the industry value chain
• Corporate leaders, strategists, financial experts, shareholders, asset managers, and governmental representatives can make long-term planning scenarios and build an integrated and timely understanding of market dynamics
• Benefit from tailored solutions and expert consultation based on report insights, providing personalized strategies aligned with specific business needs.
TABLE OF CONTENTS
1 Introduction to 2024 Liver Disease Therapeutics Market
1.1 Market Overview
1.2 Quick Facts
1.3 Scope/Objective of the Study
1.4 Market Definition
1.5 Countries and Regions Analyzed
1.6 Units, Currency, and Conversions
1.7 Industry Value Chain
2 Research Methodology
2.1 Market Size Estimation
2.2 Sources and Research Methodology
2.3 Data Triangulation
2.4 Assumptions and Limitations
3 Executive Summary
3.1 Global Liver Disease Therapeutics Market Size Outlook, $ Million, 2021 to 2030
3.2 Liver Disease Therapeutics Market Outlook by Type, $ Million, 2021 to 2030
3.3 Liver Disease Therapeutics Market Outlook by Product, $ Million, 2021 to 2030
3.4 Liver Disease Therapeutics Market Outlook by Application, $ Million, 2021 to 2030
3.5 Liver Disease Therapeutics Market Outlook by Key Countries, $ Million, 2021 to 2030
4 Market Dynamics
4.1 Key Driving Forces of Liver Disease Therapeutics Industry
4.2 Key Market Trends in Liver Disease Therapeutics Industry
4.3 Potential Opportunities in Liver Disease Therapeutics Industry
4.4 Key Challenges in Liver Disease Therapeutics Industry
5 Market Factor Analysis
5.1 Value Chain Analysis
5.2 Competitive Landscape
5.2.1 Global Liver Disease Therapeutics Market Share by Company (%), 2023
5.2.2 Product Offerings by Company
5.3 Porter’s Five Forces Analysis
5.4 Pricing Analysis and Outlook
6 Growth Outlook Across Scenarios
6.1 Growth Analysis-Case Scenario Definitions
6.2 Low Growth Scenario Forecasts
6.3 Reference Growth Scenario Forecasts
6.4 High Growth Scenario Forecasts
7 Global Liver Disease Therapeutics Market Outlook by Segments
7.1 Liver Disease Therapeutics Market Outlook by Segments, $ Million, 2021- 2030
By Treatment
Anti Viral Drugs
Targeted Therapy
Immunosuppressant Drugs
Chemotherapy Drugs
Immunoglobulin
Vaccines
Others
By End-User
Hospitals
Ambulatory Surgery Centers
Others
8 North America Liver Disease Therapeutics Market Analysis and Outlook To 2030
8.1 Introduction to North America Liver Disease Therapeutics Markets in 2024
8.2 North America Liver Disease Therapeutics Market Size Outlook by Country, 2021-2030
8.2.1 United States
8.2.2 Canada
8.2.3 Mexico
8.3 North America Liver Disease Therapeutics Market size Outlook by Segments, 2021-2030
By Treatment
Anti Viral Drugs
Targeted Therapy
Immunosuppressant Drugs
Chemotherapy Drugs
Immunoglobulin
Vaccines
Others
By End-User
Hospitals
Ambulatory Surgery Centers
Others
9 Europe Liver Disease Therapeutics Market Analysis and Outlook To 2030
9.1 Introduction to Europe Liver Disease Therapeutics Markets in 2024
9.2 Europe Liver Disease Therapeutics Market Size Outlook by Country, 2021-2030
9.2.1 Germany
9.2.2 France
9.2.3 Spain
9.2.4 United Kingdom
9.2.4 Italy
9.2.5 Russia
9.2.6 Norway
9.2.7 Rest of Europe
9.3 Europe Liver Disease Therapeutics Market Size Outlook by Segments, 2021-2030
By Treatment
Anti Viral Drugs
Targeted Therapy
Immunosuppressant Drugs
Chemotherapy Drugs
Immunoglobulin
Vaccines
Others
By End-User
Hospitals
Ambulatory Surgery Centers
Others
10 Asia Pacific Liver Disease Therapeutics Market Analysis and Outlook To 2030
10.1 Introduction to Asia Pacific Liver Disease Therapeutics Markets in 2024
10.2 Asia Pacific Liver Disease Therapeutics Market Size Outlook by Country, 2021-2030
10.2.1 China
10.2.2 India
10.2.3 Japan
10.2.4 South Korea
10.2.5 Indonesia
10.2.6 Malaysia
10.2.7 Australia
10.2.8 Rest of Asia Pacific
10.3 Asia Pacific Liver Disease Therapeutics Market size Outlook by Segments, 2021-2030
By Treatment
Anti Viral Drugs
Targeted Therapy
Immunosuppressant Drugs
Chemotherapy Drugs
Immunoglobulin
Vaccines
Others
By End-User
Hospitals
Ambulatory Surgery Centers
Others
11 South America Liver Disease Therapeutics Market Analysis and Outlook To 2030
11.1 Introduction to South America Liver Disease Therapeutics Markets in 2024
11.2 South America Liver Disease Therapeutics Market Size Outlook by Country, 2021-2030
11.2.1 Brazil
11.2.2 Argentina
11.2.3 Rest of South America
11.3 South America Liver Disease Therapeutics Market size Outlook by Segments, 2021-2030
By Treatment
Anti Viral Drugs
Targeted Therapy
Immunosuppressant Drugs
Chemotherapy Drugs
Immunoglobulin
Vaccines
Others
By End-User
Hospitals
Ambulatory Surgery Centers
Others
12 Middle East and Africa Liver Disease Therapeutics Market Analysis and Outlook To 2030
12.1 Introduction to Middle East and Africa Liver Disease Therapeutics Markets in 2024
12.2 Middle East and Africa Liver Disease Therapeutics Market Size Outlook by Country, 2021-2030
12.2.1 Saudi Arabia
12.2.2 UAE
12.2.3 Oman
12.2.4 Rest of Middle East
12.2.5 Egypt
12.2.6 Nigeria
12.2.7 South Africa
12.2.8 Rest of Africa
12.3 Middle East and Africa Liver Disease Therapeutics Market size Outlook by Segments, 2021-2030
By Treatment
Anti Viral Drugs
Targeted Therapy
Immunosuppressant Drugs
Chemotherapy Drugs
Immunoglobulin
Vaccines
Others
By End-User
Hospitals
Ambulatory Surgery Centers
Others
13 Company Profiles
13.1 Company Snapshot
13.2 SWOT Profiles
13.3 Products and Services
13.4 Recent Developments
13.5 Financial Profile
List of Companies
Abbott Laboratories
AbbVie Inc
Alnylam Pharmaceuticals Inc
Astellas Pharma Inc
Bristol-Myers Squibb Company
Endo International PLC
F. Hoffmann-La Roche Ltd.
Gilead Sciences
GlaxoSmithKline PLC
Merck & Co. Inc
Novartis AG
Pfizer Inc
Provectus Biopharmaceuticals Inc
Sanofi AG
Takeda Pharmaceutical
14 Appendix
14.1 Customization Offerings
14.2 Subscription Services
14.3 Related Reports
14.4 Publisher Expertise
By Treatment
Anti Viral Drugs
Targeted Therapy
Immunosuppressant Drugs
Chemotherapy Drugs
Immunoglobulin
Vaccines
Others
By End-User
Hospitals
Ambulatory Surgery Centers
Others
